Autolus Therapeutics Ltd – (NASDAQ:AUTL) has been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.
Analysts have set a twelve-month consensus price objective of $37.50 for the company, according to Zacks. Zacks has also given Autolus Therapeutics an industry rank of 101 out of 255 based on the ratings given to its competitors.
A number of equities analysts have recently commented on AUTL shares. Goldman Sachs Group started coverage on Autolus Therapeutics in a report on Thursday, July 26th. They issued a “neutral” rating for the company. Wells Fargo & Co started coverage on Autolus Therapeutics in a report on Tuesday, July 17th. They issued an “outperform” rating and a $38.00 price target for the company. William Blair started coverage on Autolus Therapeutics in a report on Tuesday, July 17th. They issued an “outperform” rating for the company. Finally, Jefferies Financial Group started coverage on Autolus Therapeutics in a report on Tuesday, July 17th. They issued a “buy” rating and a $37.00 price target for the company.
NASDAQ AUTL traded up $2.06 on Friday, hitting $26.90. 30,924 shares of the stock traded hands, compared to its average volume of 115,777. Autolus Therapeutics has a 12 month low of $19.17 and a 12 month high of $30.00.
About Autolus Therapeutics
Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumours. The company was incorporated in 2018 and is headquartered in London, the United Kingdom.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.